Efficacy and Safety of Fuzheng Hewei Prescription Combined with Rebam-ipide for Chronic Superficial Gastritis in Patients Diagnosed with Weakness of the Spleen and Stomach
Efficacy and Safety of Fuzheng Hewei Prescription Combined with Rebam-ipide for Chronic Superficial Gastritis in Patients Diagnosed with Weakness of the Spleen and Stomach
Objective To investigate the therapeutic effect of Fuzheng Hewei prescription combined with Rebamipide in the treatment of chronic superficial gastritis(CSG)in patients with weakness of the spleen and stomach and its impact on recurrence,and to analyze its safety.Methods In total,106 CGS patients with weakness of the spleen and stomach treated from April 2021 to January 2023 were selected and divided into observation group(n=53)and control group(n=53)ac-cording to random number table method.The control group was treated with Rebamipide tablets,and the observation group was treated with Fuzheng Hewei prescription on the basis of control group.The clinical efficacy,time to symptom improvement,traditional Chinese medicine(TCM)syndrome score and quality of life score before and after treatment,and gastric function indexes[serum endothelin-1(ET-1),epidermal growth factor(EGF),pepsinogenⅠ(PG-Ⅰ),gastrin-17(G-17)]levels were compared between the two groups,and adverse reactions and recurrence were observed.Results The total effective rate of the observation group[96.23%(51/53)]was higher than that of the control group[83.02%(44/53)],and the differ-ence was significant(P＜0.05).Time to symptom improvement was shorter in the observation group than in the control group(P＜0.01).After treatment,the TCM syndrome score of the observation group was lower than that of the control group,and the Short-Form36 Health Survey Questionnaire(SF-36)score was higher than that of control group(P＜0.01).The levels of ET-1 and EGF in the observation group were lower than those in the control group,while the levels of PG-Ⅰ and G-17 were higher than those in the control group(P＜0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).The recurrence rate of the observation group[1.89%(1/53)]was lower than that of control group[13.21%(7/53)],and the difference was significant(P＜0.05).Conclusion Fuzheng Hewei prescription combined with Rebamipide has significant clinical effect in the treatment of CSG patients with weakness of the spleen and stomach,which can improve symptoms and gastric function,improve quality of life,and reduce recurrence rate,with good safety.
关键词
扶正和胃方/瑞巴派特/慢性浅表性胃炎/脾胃虚弱证/表皮生长因子/胃蛋白酶原Ⅰ/胃泌素-17/复发
Key words
Fuzheng Hewei prescription/Rebamipide/Chronic superficial gastritis/Weakness of the spleen and stomach/Epidermal growth factor/Pepsinogen Ⅰ/Gastrin-17/Recurrence
维普
万方数据